Andy Rasdal Named to Synchron’s Board of Directors

Synchron has appointed Andy Rasdal to its Board of Directors. Rasdal has more than 30 years of experience of developing and commercializing novel medical devices.

As former CEO of DexCom Inc., he led the company through U.S. Food and Drug Administration (FDA) approval, a successful IPO, and commercialization of its continuous glucose monitor (CGM) product for diabetes. He currently serves as executive chairman of Epitel, a company that developed the first wearable, wireless EEG system to detect seizure conditions. As founding CEO of Obalon Therapeutics Inc., he led the company through FDA PMA approval, an IPO, and commercialization of an obesity product.

“Andy joining the board is a windfall for Synchron. He brings decades of operational experience in delivering first-to-market products through the FDA premarketing approval pathway,” Synchron Founder/CEO Tom Oxley said. “His career exposure to over 15 PMAs, in particular, leading DexCom through FDA approval and an eventual IPO, will be invaluable to Synchron.”

Before DexCom, Rasdal was president of Medtronic Vascular. He was vice president of Global Marketing at Arterial Vascular Engineering Inc., which was purchased by Medtronic for $4.3 billion. Prior to AVE, Rasdal also held positions at EP Technologies (EPTI), which was acquired as a public company by Boston Scientific Corp., and Advanced Cardiovascular Systems (ACS), which became the vascular division of Guidant and was ultimately acquired by Abbott.

Rasdal earned a master of management degree from the Kellogg Graduate School of Management and a B.Sc. from San Jose State University.
 
“I’m excited to join the Synchron Board of Directors. I believe in the company’s mission to become the first implantable brain computer interface to reach commercialization and help millions of people with paralysis reconnect with the world,” Rasdal stated. “My experience is relevant to Synchron, especially as they move towards pivotal study launch and eventual commercialization. Synchron has a broad technology platform with the potential to become the market-leading implantable neurotechnology company.”
 
New York, N.Y.-headquartered Synchron is a neurotechnology company developing an endovascular brain-computer interface (BCI) designed to restore functionality in patients with severe paralysis. The clinical-stage company is developing a neuroprosthesis to restore motor signaling to control digital devices and restore autonomy for individuals with motor impairment.